TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01705002
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: for Triple combination cohort an IV dose of 5 mg/kg on day 1 at 4 week interval. For the 3 weekly cohort an IV dose of 7.5 mg/kg at 3 week interval.
Study: NCT02630316
Drug: Inhaled Treprostinil
Normalized name: treprostinil Inhalation Solution
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Inhaled treprostinil (6 mcg/breath) administered four times daily
Study: NCT00914212
Drug: Comparator: sibutramine
DrugBank: Sibutramine (DB01105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose sibutramine 30 mg (2 x 15 mg) in one of three treatment periods.
Study: NCT00944684
Drug: High ribavirin dose
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin dose started according to kidney function (usually 1,800mg) and adapted according to plasma level during follow-up
Study: NCT04449874
Drug: GDC-6036
Normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The starting dose of GDC-6036 in the combination Arms B, C, D, E, F and G will be determined from Stage I Arm A (single-agent dose escalation).
Study: NCT04449874
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A 1200 milligram (mg) intravenous (IV) infusion of atezolizumab will be administered on Day 1 of 21 day cycles.
Study: NCT04449874
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab will be administered at an initial dose of 400 milligram per square meter (mg/m\^2) IV infusion followed by 250 mg/m\^2 IV infusion weekly in 21 day cycles.
Study: NCT00944684
Drug: Standard ribavirin dose
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin dose started at 1,000mg (body weight \<65kg) or 1,200mg (body weight equal or \>65kg)
Study: NCT00109850
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30mg/m\^2, bolus intravenous (IV), on Days 1 \& 8 of each cycle.
Study: NCT00109850
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 65mg/m\^2, intravenous (IV) over 30 min, on Days 1 \& 8 of each cycle.
Study: NCT01614184
Drug: Fluorescein
Normalized name: Fluorescein
DrugBank: Fluorescein (DB00693)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluorescite® (fluorescein injection, USP) 10% fluorescein sodium diluted to from 1% to 0.001% in sterile saline, 0.25 ml injected intradermally peri-tumoral or peri-areolar. A single dose regimen.
Study: NCT00307970
Drug: HFA FP MDI
Normalized name: FP-1096
DrugBank: FP-1096 (DB05310)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04449874
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A 15 milligram per kilogram (mg/kg) IV infusion of bevacizumab will be administered on Day 1 of 21 day cycles.
Study: NCT04449874
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150 mg of erlotinib will be administered PO QD in 21 day cycles.
Study: NCT04449874
Drug: GDC-1971
Normalized name: GDC-1971
DrugBank: GDC-1971 (DB17487)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The starting dose of GDC-1971 will be determined from its single-agent dose escalation.
Study: NCT04449874
Drug: Inavolisib
Normalized name: Inavolisib
DrugBank: Inavolisib (DB15275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The starting dose of inavolisib will be determined from its single-agent dose escalation.
Study: NCT00964106
Drug: Rosiglitazone
Normalized name: Rosiglitazone
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosed at 4 mg as probe for CYP2C8 pathway
Study: NCT00964106
Drug: Omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosed at 20 mg, probe for CYP2C19 pathway
Study: NCT00964106
Drug: Dextromethorphan
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosed at 30 mg, probe for CYP2D6 pathway
Study: NCT00964106
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dosed at 3 mg for Part 1, Part 2 cohorts B and C and 1 mg for Part 2 Cohort A, probe drug for CYP3A4/5 pathway
Study: NCT00964106
Drug: Ketoconazole
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosed at 400 mg once-daily Day 1 through Day 9, inhibitor of CYP3A4
Study: NCT00964106
Drug: Fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosed at 400 mg x 1 dose on day 1, 200 mg once daily on days 2 through 9, inhibitor of CYP2C9 pathway
Study: NCT00964106
Drug: Rifampin
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosed at 600 mg x 1 dose on Day 1 and Day 8, inhibitor of OATP1B1 pathway
Study: NCT00964106
Drug: Rosiglitazone
Normalized name: Rosiglitazone
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosed at 15 mg, probe drug for CYP2C8 pathway
Study: NCT00665951
Drug: Lopinavir/ritonavir
Normalized name: LOPINAVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lopinavir/ritonavir 200/50mg; 2 tablets; single dose
Study: NCT00665951
Drug: Lopinavir/ritonavir
Normalized name: LOPINAVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lopinavir/ritonavir 100/25mg; 4 sachets with granules; single dose
Study: NCT00665951
Drug: Lopinavir/ritonavir
Normalized name: LOPINAVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lopinavir/ritonavir 100/25mg; 4 tablets; single dose
Study: NCT01942447
Drug: Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00575380
Drug: AzaSite Eye Drops
Normalized name: AzaSite
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One drop two times a day for two days and once a day for the next five days.
Study: NCT03259789
Drug: Bexagliflozin tablets, 20 mg
DrugBank: Bexagliflozin (DB12236)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will receive bexagliflozin, 20 mg once daily for the duration of the study.
Study: NCT00261417
Drug: Tesaglitazar
Normalized name: Tesaglitazar
DrugBank: Tesaglitazar (DB06536)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00090116
Drug: Neramexane
Normalized name: Neramexane
DrugBank: Neramexane (DB04926)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04458558
Drug: Mifepristone
Normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive mifepristone at a preferred address by mail rather than standard care at clinic visit.
Study: NCT01672047
Drug: Vitamin D2
Normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25（OH）D level \<12 nmol/L 50000IU/weekX12week， 12-39 nmol/L 50000IU/weekX4week then，50000IU/month， 40-75 nmol/L 50000IU/month， 75-116.75nmol/L 25000IU/month， \>116.75nmol/L stopped.
Study: NCT02683889
Drug: Acthar
Normalized name: Acthar
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients will receive acthar 80 units twice a week for 6 months and will measure recurrence of FSGS
Study: NCT00801294
Drug: BIBF 1120 and BIBW 2992
Normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02497131
Drug: Brentuximab Vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab vedotin will be administered on Day 1 of each 21-day cycle. The dose of brentuximab vedotin is 1.8 mg/kg and is administered by outpatient IV infusion given over approximately 30 minutes
Study: NCT01429831
Drug: Aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: starting aripiprazole dose from 2-5mg/day, dose adjustment by every week, and maximum dose can up to 15mg/day. The duration is 6 weeks.
Study: NCT01071850
Drug: ipragliflozin
Normalized name: ipragliflozin
DrugBank: Ipragliflozin (DB11698)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: oral tablet
Study: NCT01071850
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: oral tablet
Study: NCT00574067
Drug: Buprenorphine +OTP
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Buprenorphine thrice weekly and counseling for four months while in pre-release prison, with referral for continued treatment at an opioid agonist treatment (OTP) program upon release. Such treatment lasts for 1 year in the community. Buprenorphine dosage, following an induction period,is 32 mg Mondays and Wednesdays and 48 mg Fridays
Study: NCT00574067
Drug: Buprenorphine +CHC
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Buprenorphine thrice weekly and counseling provided in pre-release prison for 4 months, with referral for continued treatment for 1 year in the community at a community health center (CHC). Following an induction period, buprenorphine dosing will be 32 mg on Mondays and Wednesdays and 48 mg on Fridays.
Study: NCT00574067
Drug: Counseling +CHC
Normalized name: CHC 2014
DrugBank: AUM-601 (DB17382)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Counseling only for 4 months in pre-release prison, with referral upon release for buprenorphine treatment and counseling at a community health center to last for 1 year. Following an induction period, buprenorphine dosing will be thrice weekly, with 32 mg on Mondays and Wednesdays and 48 mg on Fridays.
Study: NCT02291367
Drug: Duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Duloxetine Delayed-Release Capsules 60 mg
Study: NCT00602537
Drug: Venlafaxine
Normalized name: Venlafaxine
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 to 375 mg
Study: NCT00602537
Drug: Lithium Carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300 to 2400 mg
Study: NCT00703976
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab is approved by the Food and Drug Administration (FDA) for colorectal cancer and non-small cell lung cancer in combination of chemotherapy.
Study: NCT00703976
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab is approved by the FDA for head and neck cancers in patients who have failed other chemotherapy treatments.
Study: NCT00703976
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pemetrexed is approved by the Food and Drug Administration (FDA) for head and neck cancer when used in combination with radiation therapy.
Study: NCT01474187
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: initial from 50mg/m2/week and increased by 15mg/m2/week
Study: NCT02710591
Drug: Rimeporide
Normalized name: Rimeporide
DrugBank: Rimeporide (DB12861)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 1:~50 mg TID in patients with a body weight ≤ 30kg at Baseline and 75 mg TID in patients with a body weight \> 30kg at Baseline~Cohort 2:~100mg TID in patients with a body weight ≤ 30kg at baseline and 150 mg TID in patients with a body weight \> 30kg at Baseline~Cohort 3:~150 mg TID in patients with a body weight ≤ 30kg at baseline and 200 mg TID in patients with a body weight \> 30kg at Baseline~Cohort 4:~200 mg TID in patients with a body weight ≤ 30kg at Baseline and 300 mg TID mg TID in patients with a body weight \> 30kg at Baseline
Study: NCT03791294
Drug: TIAB: microcrystalline titanium dioxide with covalently linked monovalent silver ions
DrugBank: Titanium dioxide (DB09536)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TIAGIN vaginal capsule, composition: TIAB (microcrystalline titanium dioxide with covalently linked monovalent silver ions), Sodium Hyaluronate, Aloe Barbadensis Extract
Study: NCT00647894
Drug: Alprazolam Extended-Release Tablets 1 mg
Normalized name: alprazolam Extended Release Oral Tablet
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00647894
Drug: Xanax XR Tablets 1 mg
Normalized name: alprazolam Extended Release Oral Tablet [Xanax]
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02191566
Drug: S-1 (452500ACH)
DrugBank: Tegafur (DB09256)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: S-1 80 mg/m²/day from day 1 to day 14, every 21 days, for 12 months
Study: NCT02191566
Drug: OXALIPLATIN (205803BIJ)
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin 130 mg/m² for day 1, every 21 days, for 6 months
Study: NCT00242229
Drug: DVS-233 SR
Normalized name: rAAVrh74.MHCK7.DYSF.DV
DrugBank: S-23 (DB07419)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01514123
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab will be administered by IV infusion once every 2 weeks
Study: NCT00400582
Drug: Candesartan up to 32 mg daily
Normalized name: candesartan cilexetil 32 MG
DrugBank: Candesartan (DB13919)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 4 to 32 mg daily
Study: NCT04476186
Drug: Acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral syrp
Study: NCT02510950
Drug: Poly-ICLC
Normalized name: Poly-ICLC
DrugBank: Hiltonol (DB17293)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02510950
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02938013
Drug: Sofosbuvir/Velpatasvir/Voxilaprevir [SOF/VEL/VOX]
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: antiviral therapy for HCV
Study: NCT03175939
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cisplatin IV injection over 3 hours
Study: NCT03175939
Drug: 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU IV 24 hours continuous infusion
Study: NCT02938013
Drug: Sofosbuvir/Velpatasvir (SOF/VEL)
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: antiviral therapy for HCV
Study: NCT02812654
Drug: Ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ifosfamide 9 g/m2 (cycle 1 and 3)
Study: NCT03460145
Drug: Propofol 1 % Injectable Suspension
Normalized name: propofol 1 % Injectable Suspension
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol 1% (10mg/mL)
Study: NCT01043926
Drug: Suvorexant
Normalized name: Suvorexant
DrugBank: Suvorexant (DB09034)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single 20 mg dose of suvorexant will be administered as 2 x 10 mg film coated tablets on Day 1 after an overnight fast with water.
Study: NCT05184179
Drug: Olmesartan Medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmesartan Medoxomil, Amoldipine Besylate, Rosuvastatin Ca
Study: NCT00298987
Drug: Dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablets, Oral, 70 mg, Twice daily, 2 months.
Study: NCT02159287
Drug: Enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of enoxaparin per kilogram of body weight subcutaneous every 12 hour
Study: NCT00496028
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intravenous infusion
Study: NCT00496028
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: intravenous infusion
Study: NCT00925756
Drug: Maraviroc
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maraviroc will be given dose-adjusted to background HIV treatment (150 mg, 300 mg, or 600 mg twice daily)
Study: NCT02218307
Drug: Mupirocin
Normalized name: Mupirocin
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01859026
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment as outlined in study arms.
Study: NCT00638833
Drug: Memantine
Normalized name: Memantine
DrugBank: Memantine (DB01043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Memantine 30 mg/day (20-10-0)
Study: NCT02822196
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local Anesthesia using 1% Lidocaine
Study: NCT02822196
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local Anesthesia using 0.25% Bupivacaine
Study: NCT00657605
Drug: Recombinant methionyl human leptin
Normalized name: leptin human
DrugBank: Leptin (DB05098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant methionyl human leptin, subcutaneous, once a day, 0.02 to 0.04 mg/kg (adjusted according to weight loss), indeterminate duration.
Study: NCT00893451
Drug: cholecalciferol (TillVal-D)
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In a randomized, two-way cross-over design participants will take vitamin D3 or placebo twice daily during treatment periods of 10 weeks separated by a washout period of 6 weeks.
Study: NCT00333723
Drug: Rosiglitazone
Normalized name: Rosiglitazone
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00042549
Drug: ursodiol
Normalized name: Ursodiol
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00987142
Drug: CX501
Normalized name: CX501
DrugBank: CX501 (DB05174)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cultured chimeric skin
Study: NCT00440115
Drug: Bupropion
Normalized name: Bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buproprion or Nicotine Replacement Therapy
Study: NCT02631252
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doses ranging from 600-1400mg daily in divided twice daily doses and administered orally.
Study: NCT02631252
Drug: Mitoxantrone
Normalized name: Mitoxantrone
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose: 10mg/m2 IVPB in 50ml NS
Study: NCT02631252
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose: 100 mg/m2 administered intravenously in 500 ml of 0.9% sodium chloride
Study: NCT02148445
Drug: Nicotine replacement therapy
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00442546
Drug: pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 150 milligram (mg)/ day (double blind)
Study: NCT00442546
Drug: pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 300 mg/day (double blind)
Study: NCT01253317
Drug: rhIGF-1
Normalized name: rhIGF-I/rhIGFBP-3
DrugBank: Mecasermin rinfabate (DB14751)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1) Multiple ascending dose (MAD) period (4 weeks): Subjects will receive escalating twice-daily doses of IGF-1 over 4 weeks (40 µg/kg, 80 µg/kg, 120 µg/kg) and then continue treatment at 120 µg/kg BID for 20 weeks should they choose to enroll in the open-label extension period.
Study: NCT04148105
Drug: Cilostazol 100 MG
Normalized name: cilostazol 100 MG
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The addition of 100 mg cilostazol, twice daily for 14 days, to the standard treatment regimen of 60 mg nimodipine every 4 hours for 21 days and the standard aneurysmal subarachnoid treatment pathway
Study: NCT04137536
Drug: anti-EGFR-bispecific antibody armed activated T-cells
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase I:~* First 3 participants, twice weekly infusions of 10\^10 EGFR BATs infusions~* If there is toxicity in 0 or 1 of 3 participants, 3 additional participants will be added to the dose level of up to 10\^10.~* If \>/= 2 of 6 participants experience DLTs, then the dose will be reduced to 7.5 x 10\^9 per infusion~* If only 0 or 1 participants has toxicity in the first 6, then the study will proceed to enroll in the expansion cohort~Expansion cohort:~- 8 infusions of 7.5 x 10\^9 or 10\^10 EGFR BATs in 22 evaluable participants (including the 6 participants treated at the maximum tolerated dose in Phase I)
Study: NCT00660868
Drug: Pentoxifylline retard 400mg
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Agapurin retard 400mg 3/day per os for 3 weeks
Study: NCT01668823
Drug: HPPH
Normalized name: HPPH
DrugBank: 2-(1-Hexyloxyethyl)-2-devinyl pyropheophorbide-a (DB15243)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT02856087
Drug: Naloxone
Normalized name: Naloxone
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: naloxone infusion
Study: NCT03180528
Drug: Remetinostat
Normalized name: Remetinostat
DrugBank: Remetinostat (DB14869)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applied topically under bandage occlusion
Study: NCT02447887
Drug: Ixazomib
Normalized name: Ixazomib
DrugBank: Ixazomib (DB09570)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The prescribed administration of ixazomib doses in this study is 1.5-4.0 mg ixazomib weekly for 3 out of 4 weeks in each cycle (1 cycle=28 days).
Study: NCT02447887
Drug: Pegylated IFN-alpha 2b
Normalized name: Pegylated proline interferon alpha-2b
DrugBank: Ropeginterferon alfa-2b (DB15119)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly injection
Study: NCT01086345
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01263886
Drug: ombrabulin (AVE8062)
Normalized name: Ombrabulin
DrugBank: Ombrabulin (DB12882)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:solution~Route of administration: intravenous